CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 1081 - 1090 of 1137
Study Number Lead Group Study Title CIRB Study Status
S2205 SWOG Ice Compress: Randomized Trial Of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression For The Prevention Of Taxane-Induced Peripheral Neuropathy Cancer Prevention and Control CIRB Available to Open
S2206 SWOG Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
S2207 SWOG Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma Adult CIRB - Late Phase Emphasis Available to Open
S2209 SWOG A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance Adult CIRB - Late Phase Emphasis Available to Open
S2210 SWOG A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations Adult CIRB - Late Phase Emphasis Available to Open
S2212 SWOG Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study Adult CIRB - Late Phase Emphasis Available to Open
S2213 SWOG A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis Adult CIRB - Late Phase Emphasis Available to Open
S2302 SWOG Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Adult CIRB - Late Phase Emphasis Available to Open
S9910 SWOG Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary Adult CIRB - Late Phase Emphasis Completed
S9925 SWOG Lung Cancer Specimen Repository Protocol Ancillary Adult CIRB - Late Phase Emphasis Completed
Displaying 1081 - 1090 of 1137